| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Morgan R Godin | |
| Preeya K Gupta | |||
| P2860 | cites work | A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye | Q83435570 |
| Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease | Q26746232 | ||
| Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease | Q26774853 | ||
| Apoptosis of ocular surface cells in experimentally induced dry eye. | Q33185569 | ||
| Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study | Q34493904 | ||
| Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) | Q34735196 | ||
| Tear cytokine profiles in dysfunctional tear syndrome. | Q36637791 | ||
| Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study | Q36877000 | ||
| Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. | Q39730888 | ||
| Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule | Q42162451 | ||
| Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study | Q42708147 | ||
| ICAM-1 expression predisposes ocular tissues to immune-based inflammation in dry eye patients and Sjögrens syndrome-like MRL/lpr mice | Q44809776 | ||
| Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells | Q45158775 | ||
| Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). | Q46401944 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P304 | page(s) | 951-957 | |
| P577 | publication date | 2017-05-22 | |
| P1433 | published in | Clinical Ophthalmology | Q5133782 |
| P1476 | title | Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy | |
| P478 | volume | 11 |
| Q48498689 | Assessment and management of dry eye disease. |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q61443182 | Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes |
| Q58694745 | Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort |
Search more.